SOLESENCE, INC. — Director's Dealing 2021

Dec 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2021-12-28

Reporting Person: Cureton Kevin (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-28	Common Stock (right to purchase)	$4.17	A	90000	Acquired	2028-12-28	Common Stock (90000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	50821	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Common Stock (right to purchase)	$0.52	2024-02-13	Common Stock (25000)	25000	Direct
Common Stock (right to purchase)	$0.44	2025-02-18	Common Stock (50000)	50000	Direct
Common Stock (right to purchase)	$0.42	2026-02-23	Common Stock (43500)	43500	Direct
Common Stock (right to purchase)	$0.68	2027-02-21	Common Stock (50000)	50000	Direct
Common Stock (right to purchase)	$0.82	2028-05-23	Common Stock (80000)	80000	Direct
Common Stock (right to purchase)	$0.51	2029-05-22	Common Stock (16500)	16500	Direct
Common Stock (right to purchase)	$0.45	2027-06-18	Common Stock (90000)	90000	Direct

Footnotes

F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.

F2: Following the recently reported exercise of 12,393 shares (11/24/21), and the 2nd exercise of 12,607 shares (11/26/21, reported above) this line item represents the 3rd exercise, of 25,000 shares of the total initial grant of 75,000 shares, leaving a balance of 25,000 shares remaining relating to this grant.